Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)

Trial Profile

A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RATIFY
  • Sponsors Novartis
  • Most Recent Events

    • 04 Dec 2018 Results of a post hoc analysis assessing prognostic impact of FLT3-TKD and NPM1 mutations presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results assessing the Prognostic Impact of Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Nov 2018 Results assessing cost-effectiveness, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top